About Gorilla Glue #4

This strain gets its gluey name thanks to the resin that collects on the scissors when trimming. Gorilla Glue's chunky, resin-covered buds fill the room with pungent earthy and sour aromas inherited from its parent strains.

Bred by GG Strains

Gorilla Glue #4 (also known as GG4) created by GG strains is a Sativa-dominant hybrid, a multiple award-winning strain, famous for its high THC content. This strain gets its gluey name thanks to the resin that collects on the scissors when trimming. Gorilla Glue #4 has several parents due to extensive backcrossing – Sour Diesel, Sour Dubb, Chem's Sister and Chocolate Diesel.

The hybrid strain has won awards at the 2014 Cannabis Cup in both Los Angeles and Michigan. It has been described as a bunch of trichomes with a few buds, leaves, and stalks sticking out.

The aroma is very strong and is mostly diesel with notes of chocolate and coffee, although sweet and earthy is also used to describe it. You’ll be going back for seconds due to the full-bodied and flavorful smoke. The buds are green with orange hairs. It is very dense, spongy, resinous, and covered in trichomes.

GG4 averages 18 to 25% THC, but you may find it as high as 32% at some dispensaries. The CBD is very low, ranging between 0.05 and 0.1 percent.

Description provided by Wikileaf.

Information provided could come from a third-party source, and likely does not accurately reflect characteristics of the medication we're associating it with - we primarily provide these descriptions for those interested in strain lineage and history, which could also be inaccurate. Any information which could be taken as medical advice should be strictly disregarded. Please consult your doctor regarding the suitability of medications for your condition(s).

About Lyphe Group Ltd

From Lyphe Group, a range of medical flowers and oils focused on giving doctors reassurance in the efficiency and consistency of our supply chain, while providing quality pharmaceutical-grade medication.

At Lyphe our vertical operations span product manufacturing, clinical care, pharmacy dispensing and doctor education. Our direct-to-patient and technology-led approach has quickly established us as the market’s largest player, with a 30% share of all patients. We have also recently entered the Australian market, where we intend to replicate our model of success.

lyphegroup.com